News
IVBXF
10.74
+6.65%
0.67
CSC Financial Remains a Buy on Innovent Biologics (IVBXF)
TipRanks · 4h ago
Morgan Stanley Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
TipRanks · 1d ago
UBS Remains a Buy on Innovent Biologics (IVBXF)
TipRanks · 1d ago
Innovent Biologics Sets June 2026 AGM With Share Buyback and Issuance Mandates on Agenda
TipRanks · 1d ago
Pfizer signs up to $10.5B oncology deal with China’s Innovent
Seeking Alpha · 2d ago
Innovent Strikes Up to US$10.5 Billion Global Oncology Pact With Pfizer
TipRanks · 2d ago
Pfizer enters into global strategic collaboration with Innovent Biologics
TipRanks · 2d ago
Innovent Biologics (IVBXF) Receives a Buy from CSC Financial
TipRanks · 5d ago
Innovent Biologics Makes USD690 Million Structured Note Investments With JPMorgan and UBS
TipRanks · 05/22 15:12
Innovent Wins China Approval for TYVYT–ELUNATE Combo in Advanced Kidney Cancer
TipRanks · 05/21 09:09
CICC Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
TipRanks · 05/04 09:15
Analysts Are Bullish on These Healthcare Stocks: OSE Immunotherapeutics SA (DE:6OP), Innovent Biologics (IVBXF)
TipRanks · 05/03 09:01
Innovent Biologics Posts 50% Revenue Surge and Advances Global Pipeline in Q1 2026
TipRanks · 04/29 23:47
Shenwan Hongyuan Remains a Buy on Innovent Biologics (IVBXF)
TipRanks · 04/15 06:35
Innovent Biologics (IVBXF) Gets a Buy from Zhongtai Securities
TipRanks · 04/10 10:05
SDIC Securities Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
TipRanks · 04/02 06:19
Guotai Haitong Remains a Buy on Innovent Biologics (IVBXF)
TipRanks · 04/02 06:15
BOCOM International Holdings Company Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
TipRanks · 04/01 06:17
Innovent Biologics (IVBXF) Gets a Buy from CSC Financial
TipRanks · 03/31 06:56
CICC Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
TipRanks · 03/31 06:17
More
Webull provides a variety of real-time IVBXF stock news. You can receive the latest news about Innovent Biologi through multiple platforms. This information may help you make smarter investment decisions.
About IVBXF
Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.